At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Pegylated Liposomal Doxorubicin (PLD) for Ovarian Cancer and 2 related conditions. Completed, enrolled 26 participants across 3 sites.
Detailed Summary
This research study is studying the combination of Pegylated Liposomal Doxorubicin (PLD) and Pembrolizumab as a possible treatment for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer that is resistant to platinum therapy. The following interventions will be used in this study: * Pegylated liposomal doxorubicin (PLD) * Pembrolizumab
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartSep 2016
Primary CompletionAug 2020
Study CompletionMar 2022
TodayJul 2026
First PostedAug 12, 2016
Enrollment StartSep 15, 2016
Primary CompletionAug 1, 2020
Study CompletionMar 1, 2022
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.9 years ago
Interventions
Pembrolizumabdrug
Please see "Arms" for description.
Pegylated Liposomal Doxorubicin (PLD)drug
Please see "Arms" for description.